Medical Affairs Expert Guide

Overview

Medical Affairs has evolved from a reactive scientific support function into a strategic bridge between clinical evidence and real-world healthcare decisions. This guide helps Medical Affairs leaders and managers design or upgrade strategy, governance, and measurement systems so they can make operational decisions with actionable templates and checklists.

The guide covers operational domains including distinctions from Commercial and Clinical functions, phase-based medical planning, durable governance, evidence generation choices (RWE, HEOR, IITs/ISTs), an insights management loop, Medical Information operations, KOL and DOL engagement, a KPI framework with a sample scorecard, tooling selection criteria, global versus regional operating models, and career credentials. Each section provides operational specificity to inform decisions rather than just describe concepts.

---

What Medical Affairs Does and How It Differs from Commercial and Clinical

Medical Affairs bridges scientific innovation and real-world healthcare needs while operating distinctly from Commercial and Clinical teams. Practically, Medical Affairs generates, synthesizes, and communicates evidence without promotional intent. It serves HCPs, payers, patient groups, and HTA bodies with credible scientific exchange.

The clearest boundary is purpose. Commercial promotes approved indications to influence prescribing. Clinical develops the evidence for regulatory approval. Medical Affairs translates that evidence into balanced exchange, pursues post-approval evidence, and provides scientific stewardship in cross-functional decisions. As the Medical Affairs Professional Society (MAPS) notes, many Medical Affairs professionals hold doctoral-level degrees that underpin external scientific credibility.

Collaboration is as important as distinction. Medical Affairs informs R&D via field insights and advisory outputs that can reshape studies. It supports Market Access with HEOR and RWE. It works alongside Commercial to ensure scientific accuracy without co-creating promotional content. Managing and documenting those collaboration lines is the core governance challenge for the function.

Core Responsibilities and Stakeholders

Medical Affairs encompasses several interconnected responsibility areas, each linked to specific stakeholders and operational activities:

• Scientific exchange: Peer-to-peer dialogue with HCPs (physicians, pharmacists, nurses, allied health) on data, evidence gaps, and clinical questions, typically conducted by MSLs and medical directors.
• Evidence generation: Sponsorship or support for RWE, HEOR, and IITs/ISTs addressing post-approval evidence gaps.
• Medical education: Designing and funding independent medical education programs, symposia, and advisory boards to improve disease and treatment literacy.
• Publications: Managing publication planning aligned with Good Publication Practice (GPP 2022) to ensure timely, transparent, and ethical communications.
• Medical Information: Responding to unsolicited medical inquiries from HCPs, patients, and caregivers with accurate, balanced, and documented responses.
• Field insights: Capturing, triaging, and synthesizing HCP input to inform evidence strategy, the medical plan, and cross-functional decisions.

Stakeholders include external scientific communities (KOLs, academic researchers, practicing HCPs), payers and HTA bodies, patient advocacy organizations, and internal partners in R&D, Commercial, Regulatory, and Market Access.

Non-promotional Scientific Exchange Boundaries

Non-promotional scientific exchange is a governance requirement grounded in regulatory frameworks such as the PhRMA Code and OIG guidance. It demands that scientific dialogue be driven by genuine information needs, initiated appropriately, and separated from promotional activity through clear processes and documentation.

In practice, MSL interactions must not be conditioned on prescribing. Compensation should not reward commercial outcomes. Data presentation must remain balanced and include unfavorable findings.

Off-label exchange may be permitted in certain jurisdictions. It must follow documented processes, use approved response documents, and obtain legal and compliance review. U.S. laws like the Anti-Kickback Statute and Open Payments program add documentation and disclosure obligations for HCP compensation. Enforcement history shows that intent, incentive structures, and governance documentation influence regulatory scrutiny. Sustained, demonstrable processes are therefore essential.

---

Build a Phase-based Medical Plan

An effective medical plan begins with situational analysis rather than a tactical calendar. It links tactics to strategy, measurable outcomes, and compliance gates. Practically, structure the plan by product lifecycle phase (pre-launch, launch, growth, LOE/LSR). Evidence gaps, stakeholder needs, and compliance requirements change materially across those stages.

A genuine plan starts by mapping the evidence landscape, unmet medical needs, HCP knowledge gaps, and competitive context. Tactics then trace back to that strategic rationale. For example, a pre-launch oncology team that identifies disagreement on first- versus second-line positioning should plan RWE on sequencing patterns. They should prioritize a Phase III subgroup publication and design pre-launch education on patient selection — each tactic mapped to the identified gap and gated by MLR, safety, and publication controls.

Pre-launch to Launch: Objectives, Tactics, and Compliance Gates

The pre-launch window is high leverage because scientific narratives are most malleable before approval and most scrutinized afterward. Key objectives and execution requirements include:

• Objective: Disease awareness and unmet need education — Tactic: Independent medical education (IME) programs; Gate: Confirm educational grant process and IME independence from promotional review.
• Objective: KOL and clinical community engagement — Tactic: Advisory boards and trial steering committees; Gate: FMV documentation for consultants and minutes that capture insights, not promotional intent.
• Objective: Evidence gap identification — Tactic: Landscape analyses and systematic literature reviews; Gate: Medical and statistical review plus GPP-aligned publication planning.
• Objective: Medical Information infrastructure — Tactic: Draft and MLR-approve core response documents before launch; Gate: Safety review to embed AE escalation pathways.
• Objective: MSL field readiness — Tactic: Training on clinical data and non-promotional exchange; Gate: Compliance sign-off and role-play assessment.
• Compliance gate across activities: Legal, regulatory, and compliance confirmation that materials and activities do not imply promotional intent for an unapproved indication.

Growth to LOE/LSR: Sustaining Evidence and Education

Post-approval, the focus shifts from awareness to optimization and evidence deepening. RWE moves from planning to execution and readout. It is co-designed with HEOR and Market Access to address payer and HTA evidence requirements.

Publication planning intensifies with congress abstracts, post-marketing presentations, and systematic reviews to inform guidelines. Advisory boards focus on practical implementation questions such as dosing in special populations and comparative effectiveness.

Approaching LOE/LSR, evidence efforts narrow to long-term safety, registries, and endpoints that remain scientifically relevant beyond commercial windows. Effective teams deprioritize low-yield activities. They concentrate remaining budgets on data that serve patients and guideline committees rather than dwindling commercial objectives.

---

Governance That Protects Scientific Credibility

Medical Affairs governance comprises the processes, documentation requirements, approval pathways, and audit artifacts that make scientific independence demonstrable under internal audit, regulatory inspection, and leadership change. Practically, governance must be operational, not just policy on paper, to survive scrutiny and organizational shifts.

Regional compliance adds complexity. U.S. rules (PhRMA, OIG guidance, Anti-Kickback Statute, Open Payments) and European/Japanese codes (EFPIA, ABPI, JPMA) share principles like FMV compensation and documented rationale. They differ in timing, thresholds, and reporting. Country medical directors must adapt global frameworks to local legal and disclosure requirements before implementation.

MLR/PRC Workflows and SOP Essentials

An MLR/PRC SOP that produces audit-ready artifacts should include:

• Defined scope: Material types requiring MLR review (MSL leave-behinds, slide decks, SRLs, platform documents, advisory agendas, grant proposals, digital content).
• Role clarity: Author, medical reviewer, regulatory reviewer, legal reviewer, and final approver with documented sign-off.
• Review sequencing: Medical review first, followed by regulatory and legal; parallel reviews allowed if roles remain separate.
• Version control: Single source of truth, archived prior versions with change logs.
• Approval records: Date-stamped approvals with reviewer identities stored and retrievable.
• Expiry and re-review: Approval validity windows (commonly 12–24 months) and mandatory re-review upon label or data changes.
• Audit trail: Every comment, revision, approval, and rejection logged and exportable.

Teams transitioning from informal to formal MLR processes should treat SOP development as a minimum viable governance step before resuming external scientific activity.

Advisory Boards: FMV, Agendas, and Minutes

Advisory boards generate high-value scientific insight but carry enforcement risk when they act as disguised promotional forums. A compliant advisory board checklist includes:

• Scientific rationale: Documented business need for the posed scientific question.
• Participant selection criteria: Based on relevant expertise and independent of commercial input.
• FMV compensation: Calculated and documented per participant and reportable under applicable rules.
• Agenda design: Pre-circulated agenda focused on scientific questions; no promotional materials.
• Meeting format: Time structured for genuine dialogue, not briefing-then-rubber-stamp.
• Minutes: Accurate records of discussion, disagreements, and conclusions; finalized within a defined window (commonly 30 days).
• Insights capture: Structured summaries entered into the insights management system and linked to the medical plan activity that generated them.
• Conflict of interest disclosures: Collected before the meeting and included in documentation and subsequent publications as required.

---

Evidence Generation Choices: RWE, HEOR, IITs/ISTs

Choosing an evidence modality starts by articulating the specific evidence gap and prioritizing projects by impact on clinical practice, guideline inclusion, formulary access, or safety communication. RWE, HEOR, and IITs/ISTs each have distinct scopes, governance models, and compliance risk profiles. Combined or multi-purpose projects often provide disproportionate value.

Prioritization should favor projects that address multiple strategic needs. For example, a registry yielding RWE and patient-reported outcomes can support HEOR modeling. Deprioritize low external validity, duplicative, or commercially timed projects lacking scientific rationale.

When to Support an Investigator-initiated Study

An IIT/IST is investigator-led and company-supported. Supporting one requires evaluating scientific merit, investigator independence, safety alignment, feasibility, compliance risk, and resource fit.

A defensible decision framework assesses whether the study addresses a documented gap, is publishable regardless of outcome, maintains investigator independence via firewalls, has clear PV obligations, is operationally feasible, and justifies the resource investment compared with alternatives.

Approved IIT/ISTs require a formal review committee decision. They also need an executed grant agreement that delineates the company’s role and limitations. Publication rights must align with GPP 2022. A monitoring plan should track progress without directing outcomes.

Company-sponsored RWE and HEOR: Design and Guardrails

Company-sponsored RWE and HEOR offer greater design control and corresponding governance responsibility. Legitimate Medical Affairs RWE is distinguished by protocol preregistration (e.g., ClinicalTrials.gov), predefined endpoints and analysis plans, independent statistical analysis, and a commitment to publish results regardless of direction.

Study designs should follow recognized methodological standards and fully disclose sponsor involvement and author conflicts in line with GPP 2022. RWE typically addresses treatment patterns, safety signals, subgroup outcomes, and adherence in routine practice. HEOR models translate clinical outcomes into economic terms payers require. Cross-functional design with HEOR, biostatistics, and compliance improves external validity and payer relevance.

---

Insights Management Loop That Actually Changes Strategy

Field insights require a systematic loop — capture, triage, synthesis, action, feedback — with defined ownership at each stage. This converts observations into strategic change.

Capture is the field team’s responsibility using a standardized taxonomy. Triage is an insights lead’s role to prioritize and route signals. Synthesis aggregates signals on a cadence. Action updates the medical plan or escalates to evidence committees. Feedback communicates dispositions back to the field to sustain capture quality.

A consistent taxonomy and cadence enable queries such as "how many MSL interactions last quarter flagged treatment sequencing uncertainty?" These metrics justify new IIT proposals or education priorities in annual reviews.

Sample Insights Taxonomy (Fields and Definitions)

A minimum viable insight entry should include fields that enable aggregation, search, and actionability:

• Source type: MSL interaction, advisory board, Med Info inquiry, congress conversation, literature review, patient advocacy input.
• Therapeutic theme: Disease area, patient population, or treatment context (e.g., "first-line therapy in HFrEF with CKD stage 3+").
• Insight intent: Evidence gap, clinical practice question, safety concern, competitive observation, or treatment barrier.
• Evidence gap type: Real-world efficacy, comparative effectiveness, safety signal, HEOR/burden of disease, guideline applicability, dosing/administration.
• Action owner: Named individual or team responsible for response.
• Decision date: Expected or actual disposition date.
• Outcome/action taken: What changed — new RWE study, updated publication plan, revised medical plan objective, or archived with rationale.

With consistent taxonomy, teams can quantify signal frequency, weigh source credibility, and defensibly prioritize evidence activities.

---

Medical Information Operations and Safety Touchpoints

Medical Information responds to unsolicited inquiries from HCPs, patients, caregivers, and payers with accurate, balanced, and documented scientific information. It operates at the intersection of communication, compliance, and patient safety.

Practically, Medical Information must ensure unified intake, documented responses, version control, and clear AE escalation pathways. Common channels (phone, email, web forms, congress booths) must feed into a unified intake system so inquiries are not lost and every response is auditable.

Response documents (SRLs, FAQs, individualized replies) should be drafted, MLR-reviewed, approved, version-controlled, and archived. Every Med Info interaction must include structured prompts to detect potential AEs or pregnancy exposures. A formal SOP should describe reporting to pharmacovigilance within regulatory timeframes.

Audit readiness requires that inspectors can retrieve the inquiry, the response, the document version used, responder identity, and AE screening evidence in one retrievable record.

---

KOL and DOL Engagement Without Crossing Promotional Lines

Engagement with Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs) must serve genuine scientific purposes such as expert input, balanced information dissemination, and independent education. Channel differences (in-person versus digital) do not change governing principles. Transparency, FMV compensation, documented scientific rationale, and firewalls from promotional intent apply equally.

DOL engagement raises additional risks around online misinformation. The appropriate response is factual correction through scientific channels—peer exchange, published letters, or supplying accurate data to HCPs—rather than public-facing promotional counter-messaging. Any online Medical Affairs content responding to misinformation must pass MLR review and meet non-promotional standards.

Designing Compliant Scientific Education

Compliant scientific education rests on documented principles that differentiate it from promotion:

• Independence: Content developed and delivered independently; funding should not influence content selection or speaker choices.
• Balance: Programs present the full scope of evidence, including unfavorable data.
• Need-based design: Programs address documented educational gaps identified through needs assessment.
• Speaker selection: Speakers chosen for expertise, not prescribing volume; honoraria are FMV-compliant and disclosed.
• Documentation: Agenda, speaker agreements, attendee lists, materials, and evaluations retained per retention policy.
• Disclosure: Speaker conflicts of interest and company funding disclosed to attendees before the program.

---

Metrics That Demonstrate Medical Affairs Impact

Medical Affairs impact metrics must move beyond activity counts to an input → process → output → outcome framework. This framework distinguishes what was done, how efficiently it was done, what it produced, and what changed externally.

Outcome metrics should avoid sales linkages to remain defensible and compliance-safe. Instead, track proxies for clinical practice change such as guideline citations, pre/post educational assessments of HCP knowledge or intent, and payer decisions informed by HEOR outputs.

Collecting these metrics is harder than call counts but yields credible evidence of strategic value to legal, finance, and regulatory stakeholders.

Example Medical Affairs KPI Scorecard (Fields)

A functional KPI scorecard should include:

• Metric name: Concise standardized label.
• Definition: Precise operational definition for consistent measurement.
• Metric category: Input, process, output, or outcome.
• Data source: Where the measurement comes from (Medical CRM, Med Info system, publication tracker, guideline database).
• Measurement cadence: Monthly, quarterly, or annual.
• Target: Defined threshold or performance range.
• Owner: Named individual or role responsible for reporting.
• Current value: Most recent measurement.
• Trend: Direction relative to prior period and whether favorable.

Example metrics by category: Inputs — MSL FTE per indication; Process — average MLR review cycle time; Outputs — peer-reviewed publications submitted; Outcomes — HCP knowledge shift scores, guideline inclusion of company-sponsored RWE.

---

Tooling and Data Sources: How to Choose and Integrate

The Medical Affairs technology stack varies across organizations. Teams should map existing capabilities, identify gaps, and evaluate vendors against consistent criteria.

Core platform categories include Medical CRMs for MSL activity and insights capture, Medical Information systems for inquiry intake and AE escalation, MLR review platforms for approval workflows and audit trails, literature databases (PubMed, Embase, Cochrane) for evidence access, trial registries (ClinicalTrials.gov, EU Clinical Trials Register) for IIT/IST management, and RWE data sources (claims, EHR networks, registries) that require scrutiny for provenance and privacy compliance.

Regulatory submission workspaces that maintain shared version control and continuous validation checks (e.g., eCTD validator) help ensure Medical Affairs–contributed documents are structurally consistent with eCTD packaging and reduce late-stage submission rework. Integrations that avoid manual rekeying preserve data lineage and auditability across Medical Affairs and RegOps functions.

Selection Criteria and Validation Considerations

Apply the following criteria when evaluating platforms:

• Compliance features: Role-based access, audit trails, document versioning, and approval workflows that meet 21 CFR Part 11 and GxP expectations.
• Data lineage: Demonstrable origin, modification history, and chain of custody for documents and data extracts.
• Integration capability: Connectors to enterprise file systems, CRM, and MLR platforms to avoid silos and manual rekeying.
• Privacy and data governance: De-identification, data use agreements, and cross-border transfer protections for patient-level data.
• Audit logging: Exportable, tamper-evident logs readable by inspectors.
• Validation documentation: Vendor-provided IQ/OQ/PQ or equivalent that satisfies internal validation needs.
• Scalability: Support for multi-country, multi-indication operations without fragmented instances.

---

Global vs Regional Operating Models

Centralized models place strategy, evidence generation, and scientific platform ownership at global or regional headquarters with local execution under a global framework. This provides scientific consistency when labels and reimbursement profiles are similar across markets. However, centralization fails when local labeling, reimbursement requirements, or standards of care diverge materially.

A practical two-layer model combines global scientific platform ownership and publication strategy with locally adapted tactics, materials, and engagement formats. Critical enablers include defined escalation pathways for conflicts between local clinical reality and global guidance, mandatory local language and cultural adaptations, jurisdiction-specific disclosure reporting, country-responsible physician sign-off on regulated communications, and local compliance counsel review of engagement practices.

---

Career Pathways and Credentials

Medical Affairs professionals come from diverse backgrounds, including clinical, HEOR, regulatory affairs, medical communications, and clinical operations. While many hold advanced scientific degrees, the function increasingly values data literacy, evidence synthesis, and cross-functional project management alongside clinical credentials.

The MSL remains a common entry point. Transitions from HEOR, regulatory submissions, or medical writing into senior Medical Affairs roles are also common, especially in evidence generation and global strategy.

Progression to Head of Medical Affairs typically requires strategic plan ownership, governance design experience, cross-functional leadership, and data literacy to evaluate RWE/HEOR quality. It also requires the ability to communicate scientific value to non-scientific executives. Networking within the function, demonstrating data analysis competency, and building therapeutic area knowledge are practical accelerants. Credentials support structured learning but do not replace operational track record.

Certification Comparison at a Glance

Three widely recognized certification pathways serve different career stages:

• BCMAS (Board Certified Medical Affairs Specialist): Oriented to Medical Affairs professionals across functions; covers scientific exchange, medical planning, evidence generation, and compliance.
• MSL-BC (Medical Science Liaison — Board Certified): Field-role focused; centers on scientific exchange and KOL engagement; suited for practicing MSLs.
• MAPS micro-credentials: Modular, topic-specific credentials (evidence generation, digital engagement, health outcomes) for mid-career professionals to build targeted competency stacks.

MSL-BC signals field execution credibility; BCMAS signals broader function knowledge; MAPS micro-credentials signal targeted strategic depth. For leadership roles, demonstrated strategic and governance experience typically outweighs credential recognition.

---

Templates and Checklists

The on-page utilities below are minimum viable field sets for governance artifacts and are ready to copy and adapt. Expand fields based on organizational complexity, therapeutic area, and jurisdictional compliance requirements.

Medical Affairs KPI Scorecard — Core Fields

• Metric name
• Definition
• Metric category (Input / Process / Output / Outcome)
• Data source
• Measurement cadence (Monthly / Quarterly / Annual)
• Target
• Owner
• Current value
• Trend vs prior period

Insights Taxonomy — Minimum Field Set

• Source type (MSL interaction / Advisory board / Med Info inquiry / Congress / Literature / Patient advocacy)
• Therapeutic theme
• Insight intent (Evidence gap / Clinical question / Safety concern / Competitive observation / Treatment barrier)
• Evidence gap type
• Action owner
• Decision date
• Outcome / action taken

IIT/IST Decision Matrix — Evaluation Criteria

• Scientific merit (documented gap; hypothesis grounded in existing data; publishable regardless of outcome)
• Investigator independence (firewall confirmed; publication rights not conditioned on results)
• Regulatory and safety alignment (on-label scope confirmed or off-label protocol reviewed; PV obligations assigned)
• Feasibility (patient access, operational capacity, timeline realistic)
• Compliance risk (grant process transparent; agreement reviewed by legal and compliance)
• Resource fit (scientific return relative to financial and oversight burden; compared with alternatives)

Advisory Board Governance Checklist

• Scientific rationale documented and independent of commercial input
• Participant selection criteria documented; no prescriber volume criteria
• FMV compensation calculated, documented, and reportable under applicable disclosure rules
• Pre-circulated agenda with scientific questions defined; no promotional materials
• Minutes template prepared in advance; finalization timeline defined (target: 30 days post-meeting)
• Insights capture process defined; outputs entered into insights management system within defined window
• Conflict of interest disclosures collected from all participants before meeting
• Disclosure of any company involvement included in meeting documentation and any resulting publications